drugset / Trial / NCT00182767

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

NCT00182767

Phase 1/2 Completed 45 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This trial is studying the side effects and best dose of ixabepilone when given together with pegylated liposomal doxorubicin hydrochloride and to see how well they work in treating women with advanced ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer or metastatic breast cancer. Drugs used in chemotherapy, such as ixabepilone and pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Timeline

Start
2006-01
Primary completion
2012-04
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 30 mg/m2 Intravenous
Subject Ixabepilone Small molecule 16 mg/m2 Intravenous